Skip to main content

Svennilson Peter's Form 4 filing

Eikon Therapeutics, Inc. (EIKN) · filed Sep 8, 2026

Accession no.
0001193125-26-385268
Filed
Sep 8, 2026, 4:33 PM ET
Trade date
Sep 3, 2026
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $1.03M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Svennilson PeterCIK 000160607410% Owner
Kutzkey TimCIK 000161418610% Owner
Column Group IV-A, LPCIK 000179635310% Owner
Column Group IV, LPCIK 000179635410% Owner
Column Group IV GP, LPCIK 000179635610% Owner
Column Group Opportunity III, LPCIK 000193182510% Owner
TCG Opportunity III GP, LLCCIK 000193244510% Owner
Column Group Opportunity III GP, LPCIK 000193287410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 3, 2026Common StockPPurchaseAcquired+89,200$11.56F1+$1,031,044.9689,200Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)